Oftex s.r.o.
- Address
- lock Available on a paid plan
Eye Diseases (C11)
At Oftex s.r.o., the ophthalmology department focuses on improving outcomes for patients with serious eye conditions. Current research targets diabetic macular edema with the goal of preserving visual function. Another program evaluates innovative approaches for age‑related macular degeneration, including its geographic atrophy form. The team also investigates treatments for eyelid disorders such as acquired blepharoptosis and for thyroid‑related eye disease.
- Acquired Blepharoptosis
- Centre‑involved diabetic macular edema
- Geographic atrophy secondary to age‑related macular degeneration
- Neovascular age‑related macular degeneration (wet AMD)
- Thyroid eye disease
Eight active trials, led by three investigators, are designed to test the safety and effectiveness of new ocular therapies and to compare them with existing standards of care.
Ocular Physiological Phenomena (G14)
Research at the site also delves into fundamental eye functions that underpin therapeutic success. Precise measurements of best‑corrected visual acuity are used as primary endpoints to gauge treatment impact. Studies monitor proptosis response, intra‑ocular pressure changes, and inflammatory markers to better understand disease mechanisms. Additional work examines dose‑response relationships to identify optimal dosing strategies for emerging agents.
- Visual acuity assessment
- Proptosis response evaluation
- Pharmacokinetic profiling
- Intravitreal drug delivery studies
- Dose‑response relationship analysis
The eight clinical investigations conducted in Pardubice, Czechia, reflect a commitment to advancing ocular science through rigorous safety and efficacy evaluation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Oftex s.r.o.
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) | Janssen Cilag International | Phase II | Not Recruiting | Aug 2023 | Feb 2026 |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ranibizumab | 2 | Unknown | 2021-09-23 | 2024-11-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.